Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Probudur (bupivacaine) is Virpax’s post-operative, ultra-long-acting anesthetic injection product candidate for post-operative pain management that is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Probudur
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
Probudur is a single injection liposomal bupivacaine formulation. It is being evaluated in preclinical trials for the treatment of postoperative pain.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Probudur
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
Envelta (MET-LENK) is a non-addictive intranasal molecular envelope endogenous enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.
Lead Product(s): Enkephalin
Therapeutic Area: Neurology Product Name: Envelta
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
Probudur (bupivacaine) is Virpax’s post-operative, ultra-long-acting anesthetic injection product candidate for post-operative pain management that is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Probudur
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
AnQlar (quaternary ammonium palmitoyl glycol chitosan) is a nanoparticle intended to prevent the spread of negatively charged viruse such as COVID-19 and influenza via intranasal spray, and has shown to inhibit the ability of the virus to replicate at non-toxic concentrations.
Lead Product(s): Quaternary Ammonium Palmitoyl Glycol Chitosan
Therapeutic Area: Infections and Infectious Diseases Product Name: AnQlar
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Altasciences Company Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Envelta™ is an intranasal molecular envelope endogenous enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer.
Lead Product(s): Enkephalin
Therapeutic Area: Neurology Product Name: Envelta
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
Probudur (bupivacaine) is Virpax’s post-operative, ultra-long-acting anesthetic injection product candidate for post-operative pain management that is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Probudur
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
NobrXio (Cannabidiol), a candidate for nasal delivery of cannabidiol for the management of specific types of rare epilepsy syndromes in children and adults. Drug acts on endocannabinoid system which regulates many physiological responses and neuronal excitability responses.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: NobrXiol
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
NobrXiol utilizes the Nanomerics Molecular Envelope Technology (MET) as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: NobrXiol
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee.
Lead Product(s): Diclofenac Epolamine
Therapeutic Area: Musculoskeletal Product Name: Epoladerm
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kindeva Drug Delivery
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022